Bioventix PLC Logo

Bioventix PLC

BVXP.L

(3.0)
Stock Price

3.825,00 GBp

65.9% ROA

73.75% ROE

24.6x PER

Market Cap.

210.091.315,00 GBp

0% DER

3.93% Yield

63.73% NPM

Bioventix PLC Stock Analysis

Bioventix PLC Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Bioventix PLC Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (70.11%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 PBV

With a remarkably low PBV ratio (0x), the stock offers substantial upside potential at a bargain price.

4 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

5 Dividend

Investors can trust the company's impressive dividend track record, consistently distributing dividends over the past five years, showcasing a strong commitment to rewarding shareholders.

6 Revenue Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

7 Net Profit Growth

The net profit of this company has shown steady growth over the past three years, highlighting its positive financial trajectory and making it an appealing choice for potential investors.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

10 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Bioventix PLC Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Bioventix PLC Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Bioventix PLC Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Bioventix PLC Revenue
Year Revenue Growth
2010 1.973.542
2011 2.383.971 17.22%
2012 2.706.436 11.91%
2013 3.535.358 23.45%
2014 4.333.221 18.41%
2015 5.517.217 21.46%
2016 7.245.862 23.86%
2017 8.751.608 17.21%
2018 9.290.029 5.8%
2019 10.313.576 9.92%
2020 10.313.576 0%
2020 10.930.588 5.64%
2021 11.719.271 6.73%
2022 11.790.276 0.6%
2022 12.816.225 8.01%
2023 26.701.584 52%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Bioventix PLC Research and Development Expenses
Year Research and Development Expenses Growth
2010 0
2011 0 0%
2012 505.194 100%
2013 552.504 8.56%
2014 511.820 -7.95%
2015 713.715 28.29%
2016 764.480 6.64%
2017 868.515 11.98%
2018 1.116.210 22.19%
2019 1.175.602 5.05%
2020 0 0%
2020 1.201.236 100%
2021 975.317 -23.16%
2022 19.348 -4940.92%
2022 1.201.398 98.39%
2023 53.632 -2140.08%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Bioventix PLC General and Administrative Expenses
Year General and Administrative Expenses Growth
2010 657.629
2011 685.541 4.07%
2012 708.697 3.27%
2013 860.966 17.69%
2014 915.164 5.92%
2015 839.233 -9.05%
2016 998.797 15.98%
2017 1.177.711 15.19%
2018 1.268.937 7.19%
2019 1.416.766 10.43%
2020 1.416.766 0%
2020 1.506.741 5.97%
2021 1.605.446 6.15%
2022 1.749.324 8.22%
2022 1.768.950 1.11%
2023 4.127.968 57.15%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Bioventix PLC EBITDA
Year EBITDA Growth
2010 1.129.177
2011 1.549.735 27.14%
2012 1.853.725 16.4%
2013 2.402.459 22.84%
2014 3.143.115 23.56%
2015 4.171.608 24.65%
2016 5.749.994 27.45%
2017 6.963.287 17.42%
2018 7.097.918 1.9%
2019 8.093.080 12.3%
2020 8.358.628 3.18%
2020 8.483.870 1.48%
2021 9.301.900 8.79%
2022 9.080.784 -2.43%
2022 10.174.010 10.75%
2023 20.869.460 51.25%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Bioventix PLC Gross Profit
Year Gross Profit Growth
2010 1.737.227
2011 2.180.392 20.33%
2012 2.518.108 13.41%
2013 3.232.493 22.1%
2014 4.012.757 19.44%
2015 5.022.337 20.1%
2016 6.750.982 25.61%
2017 8.178.404 17.45%
2018 8.414.940 2.81%
2019 9.358.184 10.08%
2020 9.491.753 1.41%
2020 9.978.036 4.87%
2021 10.865.433 8.17%
2022 10.928.172 0.57%
2022 11.858.588 7.85%
2023 24.889.232 52.35%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Bioventix PLC Net Profit
Year Net Profit Growth
2010 884.459
2011 1.237.198 28.51%
2012 1.521.454 18.68%
2013 1.815.429 16.19%
2014 2.557.466 29.01%
2015 3.494.428 26.81%
2016 4.922.289 29.01%
2017 5.663.347 13.09%
2018 5.861.663 3.38%
2019 7.202.697 18.62%
2020 7.202.697 0%
2020 6.731.348 -7%
2021 7.674.151 12.29%
2022 7.460.760 -2.86%
2022 8.372.241 10.89%
2023 16.094.460 47.98%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Bioventix PLC Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2010 0
2011 0 0%
2012 0 0%
2013 0 0%
2014 1 0%
2015 1 0%
2016 1 0%
2017 1 100%
2018 1 0%
2019 1 0%
2020 1 0%
2020 1 0%
2021 1 0%
2022 1 0%
2022 2 0%
2023 3 66.67%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Bioventix PLC Free Cashflow
Year Free Cashflow Growth
2010 755.401
2011 1.222.398 38.2%
2012 1.319.777 7.38%
2013 1.763.381 25.16%
2014 2.031.334 13.19%
2015 3.150.763 35.53%
2016 3.935.234 19.93%
2017 5.814.506 32.32%
2018 5.792.949 -0.37%
2019 7.384.362 21.55%
2020 6.107.608 -20.9%
2021 7.549.851 19.1%
2022 2.097.858 -259.88%
2022 7.892.867 73.42%
2023 4.395.099 -79.58%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Bioventix PLC Operating Cashflow
Year Operating Cashflow Growth
2010 766.139
2011 1.239.098 38.17%
2012 1.341.108 7.61%
2013 1.765.290 24.03%
2014 2.145.084 17.71%
2015 3.171.775 32.37%
2016 3.956.937 19.84%
2017 5.922.097 33.18%
2018 5.877.467 -0.76%
2019 7.723.982 23.91%
2020 6.367.934 -21.29%
2021 7.561.607 15.79%
2022 2.103.150 -259.54%
2022 7.903.450 73.39%
2023 4.400.420 -79.61%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Bioventix PLC Capital Expenditure
Year Capital Expenditure Growth
2010 10.738
2011 16.700 35.7%
2012 21.331 21.71%
2013 1.909 -1017.39%
2014 113.750 98.32%
2015 21.012 -441.36%
2016 21.703 3.18%
2017 107.591 79.83%
2018 84.518 -27.3%
2019 339.620 75.11%
2020 260.326 -30.46%
2021 11.756 -2114.41%
2022 5.292 -122.15%
2022 10.583 50%
2023 5.321 -98.89%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Bioventix PLC Equity
Year Equity Growth
2010 2.677.392
2011 3.339.686 19.83%
2012 4.204.825 20.57%
2013 5.236.164 19.7%
2014 6.584.125 20.47%
2015 8.207.373 19.78%
2016 10.144.620 19.1%
2017 11.010.966 7.87%
2018 10.826.303 -1.71%
2019 12.520.927 13.53%
2020 11.820.314 -5.93%
2021 11.821.150 0.01%
2022 12.063.773 2.01%
2023 11.434.433 -5.5%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Bioventix PLC Assets
Year Assets Growth
2010 2.868.013
2011 3.553.230 19.28%
2012 4.512.164 21.25%
2013 5.767.077 21.76%
2014 6.901.969 16.44%
2015 8.775.230 21.35%
2016 10.380.678 15.47%
2017 11.875.623 12.59%
2018 11.613.730 -2.26%
2019 13.299.795 12.68%
2020 12.907.170 -3.04%
2021 13.117.591 1.6%
2022 13.281.711 1.24%
2023 13.148.538 -1.01%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Bioventix PLC Liabilities
Year Liabilities Growth
2010 190.621
2011 213.544 10.73%
2012 307.339 30.52%
2013 530.913 42.11%
2014 317.844 -67.04%
2015 567.857 44.03%
2016 236.058 -140.56%
2017 864.657 72.7%
2018 787.427 -9.81%
2019 778.868 -1.1%
2020 1.086.856 28.34%
2021 1.296.441 16.17%
2022 1.217.938 -6.45%
2023 1.714.105 28.95%

Bioventix PLC Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
2.57
Net Income per Share
1.64
Price to Earning Ratio
24.6x
Price To Sales Ratio
15.45x
POCF Ratio
26.44
PFCF Ratio
26.08
Price to Book Ratio
18.65
EV to Sales
15.05
EV Over EBITDA
18.84
EV to Operating CashFlow
25.38
EV to FreeCashFlow
25.39
Earnings Yield
0.04
FreeCashFlow Yield
0.04
Market Cap
0,21 Bil.
Enterprise Value
0,20 Bil.
Graham Number
8.91
Graham NetNet
1.61

Income Statement Metrics

Net Income per Share
1.64
Income Quality
0.93
ROE
0.74
Return On Assets
0.66
Return On Capital Employed
0.94
Net Income per EBT
0.8
EBT Per Ebit
1.01
Ebit per Revenue
0.79
Effective Tax Rate
0.2

Margins

Sales, General, & Administrative to Revenue
0.14
Research & Developement to Revenue
0.09
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.93
Operating Profit Margin
0.79
Pretax Profit Margin
0.8
Net Profit Margin
0.64

Dividends

Dividend Yield
0.04
Dividend Yield %
3.93
Payout Ratio
0.92
Dividend Per Share
1.58

Operating Metrics

Operating Cashflow per Share
1.52
Free CashFlow per Share
1.52
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0.04
Return on Invested Capital
0.75
Return on Tangible Assets
0.66
Days Sales Outstanding
159.05
Days Payables Outstanding
681.13
Days of Inventory on Hand
233.67
Receivables Turnover
2.29
Payables Turnover
0.54
Inventory Turnover
1.56
Capex per Share
0

Balance Sheet

Cash per Share
1,04
Book Value per Share
2,16
Tangible Book Value per Share
2.16
Shareholders Equity per Share
2.16
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
-0.51
Current Ratio
7.04
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
10831129
Working Capital
0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,01 Bil.
Average Payables
0,00 Bil.
Average Inventory
575550.5
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Bioventix PLC Dividends
Year Dividends Growth
2014 14
2015 33 56.25%
2016 37 11.11%
2017 60 40%
2018 80 25%
2019 77 -3.9%
2020 89 13.48%
2021 81 -9.88%
2022 78 -3.85%
2023 152 48.68%
2024 68 -123.53%

Bioventix PLC Profile

About Bioventix PLC

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.

CEO
Mr. Peter John Harrison MA
Employee
12
Address
27–28 Eastcastle Street
London, W1W 8DH

Bioventix PLC Executives & BODs

Bioventix PLC Executives & BODs
# Name Age
1 Mr. Peter John Harrison MA
Chief Executive Officer & Director
70
2 Mr. Bruce Edward Heath Hiscock
Chief Financial Officer & Director
70

Bioventix PLC Competitors

AB Dynamics plc Logo
AB Dynamics plc

ABDP.L

(1.8)
Craneware plc Logo
Craneware plc

CRW.L

(2.0)
Tristel plc Logo
Tristel plc

TSTL.L

(1.8)
Focusrite plc Logo
Focusrite plc

TUNE.L

(3.2)